| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $794,670 | 17 | 100 |
| Kenkare-Mitra Sara | President and Head of R&D | 0 | $0 | 1 | $46,673 | $-46,673 |
| Wong-Sarad Grace | Principal Accounting Officer | 0 | $0 | 10 | $81,256 | $-81,256 |
| Berkley Neil Lindsay | Chief Bus Ofcr & Interim CFO | 0 | $0 | 3 | $182,619 | $-182,619 |
| Rosenthal Arnon | Chief Executive Officer | 0 | $0 | 3 | $484,122 | $-484,122 |
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May …
Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $794,670 worth of Alector, Inc. stock.
On average, over the past 5 years, insiders at Alector, Inc. have bought $0 and sold $5.18M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.
| 2026-09-04 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 3,625 0.0033% | $2.51 | $9,094 | -20.73% | |
| 2026-09-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 72,606 0.0694% | $2.66 | $193,473 | -22.31% | |
| 2026-09-03 | Sale | Berkley Neil Lindsay | CFO & Chief Business Officer | 29,251 0.028% | $2.66 | $77,948 | -22.31% | |
| 2026-09-03 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 5,165 0.0049% | $2.67 | $13,767 | -22.31% | |
| 2026-09-02 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 656 0.0006% | $2.75 | $1,804 | -28.31% | |
| 2026-04-16 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 1,820 0.0017% | $2.65 | $4,823 | -21.18% | |
| 2026-03-10 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 1,000 0.0011% | $2.65 | $2,650 | -13.87% | |
| 2026-03-03 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 3,367 0.0029% | $2.08 | $7,012 | -2.61% | |
| 2026-03-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 81,864 0.0655% | $2.12 | $173,822 | -6.79% | |
| 2026-03-02 | Sale | Berkley Neil Lindsay | CFO & Chief Business Officer | 29,649 0.0237% | $2.12 | $62,954 | -6.79% | |
| 2026-03-02 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 8,071 0.0065% | $2.12 | $17,138 | -6.79% | |
| 2026-02-26 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 4,079 0.0036% | $2.50 | $10,198 | -19.53% | |
| 2025-12-05 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 4,753 0.0047% | $1.21 | $5,751 | +61.48% | |
| 2025-12-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 104,347 0.1036% | $1.12 | $116,827 | +72.37% | |
| 2025-12-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 41,687 0.0414% | $1.12 | $46,673 | +72.37% | |
| 2025-12-03 | Sale | Berkley Neil Lindsay | Chief Bus Ofcr & Interim CFO | 37,261 0.037% | $1.12 | $41,717 | +72.37% | |
| 2025-12-03 | Sale | Wong-Sarad Grace | Principal Accounting Officer | 8,056 0.008% | $1.12 | $9,019 | +72.37% | |
| 2025-09-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 51,562 0.0491% | $2.50 | $128,740 | -23.36% | |
| 2025-09-02 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 23,638 0.0225% | $2.50 | $59,019 | -23.36% | |
| 2025-09-02 | Sale | Berkley Neil Lindsay | Principal Financial Officer | 15,842 0.0151% | $2.50 | $39,554 | -23.36% |
| GORDON CARL L | 10434976 9.3456% | $21.39M | 1 | 0 | +10.01% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 1906718 1.7077% | $3.91M | 1 | 17 | +10.01% |
| Wehner David M. | director | 44621 0.04% | $91,473.05 | 1 | 0 | <0.0001% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$6,146,922 | 96 | -4.70% | $233.68M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$3,668,031 | 23 | 2.05% | $243.03M |
| Increased Positions | 67 | +35.83% | 38M | +50.82% |
| Decreased Positions | 80 | -42.78% | 27M | -36.8% |
| New Positions | 25 | New | 23M | New |
| Sold Out Positions | 40 | Sold Out | 9M | Sold Out |
| Total Postitions | 174 | -6.95% | 85M | +14.01% |
| Fmr Llc | $23,228.00 | 13.93% | 15.18M | +182,960 | +1.22% | 2025-09-30 |
| Blackrock, Inc. | $11,013.00 | 6.6% | 7.2M | -775,607 | -9.73% | 2025-09-30 |
| Rtw Investments, Lp | $10,696.00 | 6.41% | 6.99M | +7M | New | 2025-09-30 |
| Vanguard Group Inc | $9,233.00 | 5.54% | 6.03M | +46,955 | +0.78% | 2025-09-30 |
| Merck & Co., Inc. | $5,425.00 | 3.25% | 3.55M | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $3,631.00 | 2.18% | 2.37M | +202,597 | +9.34% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $3,343.00 | 2.01% | 2.19M | -3M | -55.18% | 2025-09-30 |
| Geode Capital Management, Llc | $2,848.00 | 1.71% | 1.86M | -120,810 | -6.09% | 2025-09-30 |
| State Street Corp | $2,654.00 | 1.59% | 1.73M | +24,777 | +1.45% | 2025-09-30 |
| Eversept Partners, Lp | $2,278.00 | 1.37% | 1.49M | -497,347 | -25.04% | 2025-09-30 |